A Phase 3 interventional study of Sitagliptin and Glipizide in Diabetes Mellitus, Type 2 and End-Stage Kidney Disease, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2017-05-12.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 90th largest by enrollment of the 197 interventional ones that give a count, is one of 17 that started in 2007, is one of 74 in phase 3, and was the 30th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Beijing Chao Yang Hospital · Sites in China
Ages 18–65
Bahria University · Sites in Pakistan
Ages 30–55
Yonsei University · Sites in Korea, Republic of
Ages 19–75
By country, each count listing its studies:
sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 30 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
198 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 11 · Phase 3 74 · Phase 4 68
First in 2003; this study’s year is marked. 17 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 129 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 102 across the 197 interventional studies. Of the 172 that completed or were terminated, 117 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
103 of 198 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 181 finished, 150 (83%) have results posted.
Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one is the 98th largest by enrollment of the 170 interventional ones that give a count, is one of 19 that started in 2007, is one of 86 in phase 3, and was the 27th registered.
Merck & Co., Inc’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 181 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to compare sitagliptin and glipizide in lowering blood sugar in participants with type-2 diabetes mellitus (T2DM) and end-stage renal disease on dialysis who do not have adequate glycemic control.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Sitagliptin
Drug: Glipizide
25 mg (one 25-mg tablet) once daily
Also known as: MK-0431
2.5 mg (1/2 of a 5-mg tablet) once daily, up to 10 mg twice daily (four 5-mg tablets), for a maximum of 20 mg
Also known as: Glucotrol
Change From Baseline in Hemoglobin A1c After Sitagliptin Treatment
Change from baseline in mean hemoglobin A1c after treatment with sitagliptin for 54 weeks. Hemoglobin A1c is the percent of hemoglobin that is glycated. Results for the glipizide arm are not reported in this table because the primary outcome measure is for the sitagliptin arm only.
Time frame: Baseline / Week 54
Number of Participants With Clinical Adverse Events
Reported experiences assessed by investigators as adverse events, excluding data after initiation of glycemic rescue therapy.
Time frame: 54 Week Treatment Period + 28 days
Number of Participants With Symptomatic Hypoglycemic Adverse Events
A symptomatic hypoglycemic adverse event is an episode with clinical symptoms attributed to hypoglycemia, without regard to fingerstick glucose level.
Time frame: 54 Week Treatment Period + 28 days
Change From Baseline in Fasting Plasma Glucose (FPG)
Change from baseline in mean Fasting Plasma Glucose after treatment with sitagliptin versus glipizide for 54 weeks.
Time frame: Baseline / Week 54
Change From Baseline in Hemoglobin A1c for Sitagliptin Versus Glipizide Treatment
Change from baseline in least square means hemoglobin A1c after treatment with sitagliptin versus glipizide for 54 weeks. Hemoglobin A1c is the percent of hemoglobin that is glycated.
Time frame: Baseline / Week 54
| Milestone | Sitagliptin 25 mg | Glipizide 2.5 mg - 20 mg |
|---|---|---|
| Started | 64 | 65 |
| Completed | 47 | 45 |
| Not completed | 17 | 20 |
| Withdrew: Adverse event | 7 | 9 |
| Withdrew: Withdrawal by subject | 5 | 10 |
| Withdrew: Protocol violation | 3 | 0 |
| Withdrew: Excluded medication | 1 | 1 |
| Withdrew: Scheduled kidney transplant | 1 | 0 |
Change from baseline in mean hemoglobin A1c after treatment with sitagliptin for 54 weeks. Hemoglobin A1c is the percent of hemoglobin that is glycated. Results for the glipizide arm are not reported in this table because the primary outcome measure is for the sitagliptin arm only.
| Percent hemoglobin A1c | Sitagliptin 25 mg |
|---|---|
| Baseline | 7.89 ± 0.74 |
| Week 54 | 7.15 ± 0.98 |
| Change from Baseline at Week 54 | -0.74 ± 0.95 |
A symptomatic hypoglycemic adverse event is an episode with clinical symptoms attributed to hypoglycemia, without regard to fingerstick glucose level.
| Participants | Sitagliptin 25 mg | Glipizide 2.5 mg - 20 mg |
|---|---|---|
| Number of Participants With Symptomatic Hypoglycemic Adverse Events | 4 | 7 |
Reported experiences assessed by investigators as adverse events, excluding data after initiation of glycemic rescue therapy.
| Participants | Sitagliptin 25 mg | Glipizide 2.5 mg - 20 mg |
|---|---|---|
| Number of Participants With Clinical Adverse Events | 53 | 52 |
Change from baseline in mean Fasting Plasma Glucose after treatment with sitagliptin versus glipizide for 54 weeks.
| mg/dL | Sitagliptin 25 mg | Glipizide 2.5 mg - 20 mg |
|---|---|---|
| Baseline | 160.3 ± 48.5 | 167.0 ± 56.2 |
| Week 54 | 135.8 ± 40.4 | 134.0 ± 58.2 |
| Change from Baseline to Week 54 | -24.5 ± 47.5 | -33.0 ± 55.9 |
Change from baseline in least square means hemoglobin A1c after treatment with sitagliptin versus glipizide for 54 weeks. Hemoglobin A1c is the percent of hemoglobin that is glycated.
| Percent hemoglobin A1c | Sitagliptin 25 mg | Glipizide 2.5 mg - 20 mg |
|---|---|---|
| Change From Baseline in Hemoglobin A1c for Sitagliptin Versus Glipizide Treatment | -0.72 (-0.95 to -0.48) | -0.87 (-1.11 to -0.63) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sitagliptin 25 mg | — | 23/64 (35.9%) | 33/64 (51.6%) |
| Glipizide 2.5 mg - 20 mg | — | 22/65 (33.8%) | 37/65 (56.9%) |
| Event | Sitagliptin 25 mg | Glipizide 2.5 mg - 20 mg |
|---|---|---|
| Catheter site infectionInfections and infestations | 0/64 | 4/65 |
| Device malfunctionGeneral disorders | 2/64 | 0/65 |
| GastroenteritisInfections and infestations | 2/64 | 1/65 |
| Septic shockInfections and infestations | 2/64 | 0/65 |
| Urinary tract infectionInfections and infestations | 2/64 | 1/65 |
| Subdural haematomaInjury, poisoning and procedural complications | 2/64 | 0/65 |
| Acute pulmonary oedemaRespiratory, thoracic and mediastinal disorders | 2/64 | 0/65 |
| Cardiac failure congestiveCardiac disorders | 1/64 | 2/65 |
| PeritonitisGastrointestinal disorders | 0/64 | 2/65 |
| Device related infectionInfections and infestations | 1/64 | 2/65 |
| Event | Sitagliptin 25 mg | Glipizide 2.5 mg - 20 mg |
|---|---|---|
| Blood glucose decreasedInvestigations | 11/64 | 18/65 |
| CoughRespiratory, thoracic and mediastinal disorders | 7/64 | 6/65 |
| Upper respiratory tract infectionInfections and infestations | 3/64 | 7/65 |
| HypoglycaemiaMetabolism and nutrition disorders | 4/64 | 7/65 |
| HypertensionVascular disorders | 5/64 | 6/65 |
| Urinary tract infectionInfections and infestations | 5/64 | 1/65 |
| DiarrhoeaGastrointestinal disorders | 2/64 | 5/65 |
| Oedema peripheralGeneral disorders | 1/64 | 5/65 |
| Blood glucose increasedInvestigations | 4/64 | 5/65 |
| VomitingGastrointestinal disorders | 4/64 | 2/65 |
| Age, Continuous(years) | Sitagliptin 25 mg | Glipizide 2.5 mg - 20 mg | Total |
|---|---|---|---|
| Mean | 60.5 ± 9.1 | 58.5 ± 9.9 | 59.5 ± 9.5 |
| Sex: Female, Male(Participants) | Sitagliptin 25 mg | Glipizide 2.5 mg - 20 mg | Total |
|---|---|---|---|
| Female | 24 | 28 | 52 |
| Male | 40 | 37 | 77 |
No study locations are listed for this record.
Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php
Ran from Oct 2007 to primary completion in Mar 2011, 40 months.
Results were first posted in May 2012, 1 year 1 month after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 40 months is above that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sitagliptin